Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity
- PMID: 22383801
- PMCID: PMC3335380
- DOI: 10.1182/blood-2011-11-392951
Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity
Abstract
Natural killer (NK) cells are innate lymphocytes that play an important role against viral infections and cancer. This effect is achieved through a complex mosaic of inhibitory and activating receptors expressed by NK cells that ultimately determine the magnitude of the NK-cell response. The T-cell immunoglobulin- and mucin domain-containing (Tim)-3 receptor was initially identified as a T-helper 1-specific type I membrane protein involved in regulating T-cell responses. Human NK cells transcribe the highest amounts of Tim-3 among lymphocytes. Tim-3 protein is expressed on essentially all mature CD56(dim)CD16(+) NK cells and is expressed heterogeneously in the immature CD56(bright)CD16(-) NK-cell subset in blood from healthy adults and in cord blood. Tim-3 expression was induced on CD56(bright)CD16(-) NK cells after stimulation with IL-15 or IL-12 and IL-18 in vitro, suggesting that Tim-3 is a maturation marker on NK cells. Whereas Tim-3 has been used to identify dysfunctional T cells, NK cells expressing high amounts of Tim-3 are fully responsive with respect to cytokine production and cytotoxicity. However, when Tim-3 was cross-linked with antibodies it suppressed NK cell-mediated cytotoxicity. These findings suggest that NK-cell responses may be negatively regulated when NK cells encounter target cells expressing cognate ligands of Tim-3.
Figures





Similar articles
-
Natural Killer Cells Generated From Human Induced Pluripotent Stem Cells Mature to CD56brightCD16+NKp80+/-In-Vitro and Express KIR2DL2/DL3 and KIR3DL1.Front Immunol. 2021 May 4;12:640672. doi: 10.3389/fimmu.2021.640672. eCollection 2021. Front Immunol. 2021. PMID: 34017328 Free PMC article.
-
CD56brightCD16+ NK cells: a functional intermediate stage of NK cell differentiation.J Immunol. 2011 Jun 15;186(12):6753-61. doi: 10.4049/jimmunol.1100330. Epub 2011 May 9. J Immunol. 2011. PMID: 21555534
-
CD16 cross-linking induces increased expression of CD56 and production of IL-12 in peripheral NK cells.Cell Immunol. 2010;264(1):86-92. doi: 10.1016/j.cellimm.2010.05.002. Epub 2010 May 10. Cell Immunol. 2010. PMID: 20553754
-
The biology of human natural killer-cell subsets.Trends Immunol. 2001 Nov;22(11):633-40. doi: 10.1016/s1471-4906(01)02060-9. Trends Immunol. 2001. PMID: 11698225 Review.
-
CD56bright natural killer (NK) cells: an important NK cell subset.Immunology. 2009 Apr;126(4):458-65. doi: 10.1111/j.1365-2567.2008.03027.x. Immunology. 2009. PMID: 19278419 Free PMC article. Review.
Cited by
-
The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake.Immunity. 2021 Jun 8;54(6):1154-1167.e7. doi: 10.1016/j.immuni.2021.04.019. Epub 2021 May 11. Immunity. 2021. PMID: 33979578 Free PMC article.
-
Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches.Front Immunol. 2016 Apr 21;7:152. doi: 10.3389/fimmu.2016.00152. eCollection 2016. Front Immunol. 2016. PMID: 27148271 Free PMC article. Review.
-
CD3(bright)CD56(+) T cells associate with pegylated interferon-alpha treatment nonresponse in chronic hepatitis B patients.Sci Rep. 2016 May 13;6:25567. doi: 10.1038/srep25567. Sci Rep. 2016. PMID: 27174425 Free PMC article. Clinical Trial.
-
A novel soluble form of Tim-3 associated with severe graft-versus-host disease.Biol Blood Marrow Transplant. 2013 Sep;19(9):1323-30. doi: 10.1016/j.bbmt.2013.06.011. Epub 2013 Jun 17. Biol Blood Marrow Transplant. 2013. PMID: 23791624 Free PMC article.
-
NK cells as powerful therapeutic tool in cancer immunotherapy.Cell Oncol (Dordr). 2024 Jun;47(3):733-757. doi: 10.1007/s13402-023-00909-3. Epub 2024 Jan 3. Cell Oncol (Dordr). 2024. PMID: 38170381 Review.
References
-
- Vilches C, Parham P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol. 2002;20:217–251. - PubMed
-
- Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22(11):633–640. - PubMed
-
- Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol. 1986;136(12):4480–4486. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R21 AI060379/AI/NIAID NIH HHS/United States
- AI68498/AI/NIAID NIH HHS/United States
- AI076014/AI/NIAID NIH HHS/United States
- AI64520/AI/NIAID NIH HHS/United States
- R56 AI083112/AI/NIAID NIH HHS/United States
- R01 AI068498/AI/NIAID NIH HHS/United States
- R21 AI076014/AI/NIAID NIH HHS/United States
- R01 AI080129/AI/NIAID NIH HHS/United States
- K01 AI066917/AI/NIAID NIH HHS/United States
- AI068129/AI/NIAID NIH HHS/United States
- P01 AI064520/AI/NIAID NIH HHS/United States
- AI066917/AI/NIAID NIH HHS/United States
- AI60379/AI/NIAID NIH HHS/United States
- AI080129/AI/NIAID NIH HHS/United States
- AI083112/AI/NIAID NIH HHS/United States
- R01 AI060379/AI/NIAID NIH HHS/United States
- P30 AI027763/AI/NIAID NIH HHS/United States
- R01 AI068129/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous